Encision Inc (ECIA)
OTHER OTC:ECIA
Top Page
Encision
(OTC:ECIA)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.11
▼(-25.00% Downside)
Action:UpgradedDate:03/24/26
ECIA scores low primarily due to weak financial performance (ongoing losses, inconsistent cash flow, and major TTM balance-sheet red flags). Technical indicators also remain bearish, valuation is constrained by loss-making fundamentals, and the planned SEC deregistration adds additional transparency and liquidity risk.
Positive Factors
Healthy gross margin
A sustained ~53% gross margin indicates the product economics are fundamentally sound. That margin buffer supports long-term profitability if operating expenses are controlled or scaled; it also gives management flexibility to invest in R&D or sales without immediately compressing unit economics.
Negative Factors
TTM loss-making and revenue decline
Persistent negative TTM margins and ongoing revenue contraction signal the core business is not currently self-sustaining. Continued losses erode equity and limit reinvestment ability, forcing reliance on external funding or cost cuts that can impair long-term growth prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Healthy gross margin
A sustained ~53% gross margin indicates the product economics are fundamentally sound. That margin buffer supports long-term profitability if operating expenses are controlled or scaled; it also gives management flexibility to invest in R&D or sales without immediately compressing unit economics.
Read all positive factors
Encision (ECIA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.86M
Dividend YieldN/A
Average Volume (3M)16.18K
Price to Earnings (P/E)―
Beta (1Y)0.16
Revenue Growth-2.97%
EPS Growth56.17%
CountryUS
Employees22
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)N/A
Shares Outstanding16,879,644
10 Day Avg. Volume10,380
30 Day Avg. Volume16,177
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)3.45
Price to Sales (P/S)0.87
P/FCF Ratio-42.25
Enterprise Value/Market Cap1.52
Enterprise Value/Revenue0.45
Enterprise Value/Gross Profit0.85
Enterprise Value/Ebitda-11.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Encision Business Overview & Revenue Model
Company Description
Encision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. The company provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient...
How the Company Makes Money
null...
Encision Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
28
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.30M | 6.56M | 6.59M | 7.35M | 7.67M | 7.54M |
| Gross Profit | 3.32M | 3.51M | 3.14M | 4.03M | 3.79M | 3.90M |
| EBITDA | -239.94K | -95.08K | -544.20K | -217.51K | 55.10K | 760.82K |
| Net Income | -380.94K | -220.20K | -691.78K | -366.00K | 463.34K | 584.73K |
Balance Sheet | ||||||
| Total Assets | 4.06M | 3.67M | 3.81M | 4.13M | 4.79M | 5.66M |
| Cash, Cash Equivalents and Short-Term Investments | 71.73K | 257.43K | 42.51K | 189.00K | 950.00K | 1.47M |
| Total Debt | 1.53M | 1.31M | 1.33M | 1.08M | 1.15M | 2.00M |
| Total Liabilities | 2.19M | 2.02M | 1.98M | 1.64M | 2.05M | 2.86M |
| Stockholders Equity | 1.86M | 1.65M | 1.83M | 2.50M | 2.75M | 2.80M |
Cash Flow | ||||||
| Free Cash Flow | -208.51K | -134.97K | 107.57K | -1.04M | -480.00K | 175.00K |
| Operating Cash Flow | -287.98K | -54.95K | 144.39K | -861.00K | -444.00K | 220.00K |
| Investing Cash Flow | -67.17K | -80.03K | -36.82K | -183.00K | -36.00K | -45.00K |
| Financing Cash Flow | 132.63K | 349.90K | -254.02K | 284.00K | -44.00K | 914.00K |
Encision Technical Analysis
Negative
0.14
Price Trends
0.14
Negative
0.17
Negative
0.24
Negative
Market Momentum
>-0.01
Positive
40.57
Neutral
48.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ECIA, the sentiment is Negative. The current price of 0.14 is above the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.14, and below the 200-day MA of 0.24, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.57 is Neutral, neither overbought nor oversold. The STOCH value of 48.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ECIA.
Encision Risk Analysis
Encision disclosed 14 risk factors in its most recent earnings report. Encision reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Encision Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $1.59M | -2.02 | ― | ― | ― | ― | |
43 Neutral | $1.29M | -0.18 | ― | ― | ― | 60.83% | |
42 Neutral | $6.80M | -0.73 | -74.10% | ― | 53.22% | 72.69% | |
41 Neutral | $1.86M | -5.16 | -21.36% | ― | -2.97% | 56.17% |
* Healthcare Sector Average
ECIA
Encision
0.11
-0.37
-77.08%
GCTK
GlucoTrack
0.66
-9.09
-93.19%
LUCY
Innovative Eyewear, Inc.
1.08
-1.27
-54.04%
WOK
WORK Medical Technology Group LTD
1.30
-3,699.70
-99.96%
Encision Corporate Events
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
Encision to Deregister Common Stock and End SEC Reporting
Negative
Jan 29, 2026
On January 29, 2026, Encision Inc. announced that its board had approved the voluntary deregistration of its common stock with the Securities and Exchange Commission by filing a Form 15 under Section 12(g) of the Exchange Act. The move, expected t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.